These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cost effective diagnosis and treatment of atherosclerosis. Canadian Cardiovascular Society. Frohlich JJ Can J Cardiol; 1995 May; 11 Suppl C():41C-42C. PubMed ID: 7750050 [No Abstract] [Full Text] [Related]
7. Can we measure and predict atherosclerotic progression? Furberg CD Circulation; 1993 Mar; 87(3 Suppl):II82. PubMed ID: 8443928 [No Abstract] [Full Text] [Related]
8. [Diagnostic value of lipids and apolipoproteins for assessment of atherogenic risk]. Herrmann W; Hanf S; Schütz C; Lindhofer HG; Schmidt H; Strauss HJ; Schaedel H; Oswald B Z Gesamte Inn Med; 1988 Feb; 43(4):86-92. PubMed ID: 3376506 [TBL] [Abstract][Full Text] [Related]
9. [Apolipoproteins as risk factors of atherosclerosis]. Dargel R; Winkler L Z Med Lab Diagn; 1989; 30(1):35-6. PubMed ID: 2718575 [No Abstract] [Full Text] [Related]
11. Apolipoproteins as markers and managers of coronary risk. Chan DC; Watts GF QJM; 2006 May; 99(5):277-87. PubMed ID: 16504986 [TBL] [Abstract][Full Text] [Related]
12. [Value of apolipoprotein B determination in evaluation of atherogenic risk]. Messaoudia Y Arch Inst Pasteur Tunis; 1982 Mar; 59(1):217-20. PubMed ID: 7181567 [No Abstract] [Full Text] [Related]
13. [Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors]. Parhofer KG MMW Fortschr Med; 2001 Jan; 143(4):22-4. PubMed ID: 11219276 [TBL] [Abstract][Full Text] [Related]
14. [Apolipoproteins in the evaluation of familial susceptibility to atherosclerosis]. Jirkovská A; Válek J; Grafnetter D; Vondra K; Skibová J Cas Lek Cesk; 1984 Feb; 123(5):130-2. PubMed ID: 6697360 [No Abstract] [Full Text] [Related]
15. Apolipoproteins: significance for lipid metabolism and for diagnosis of atherosclerotic disease. Kostner GM; Wurm H; Zechner R; Pilger E; Dieplinger H Prog Clin Biol Res; 1985; 188():67-77. PubMed ID: 4059260 [No Abstract] [Full Text] [Related]
16. [Arterial occlusive disease as marker illness--interview with Prof. Dr. Curt Diehm. Discover the "silent majority"!]. Diehm C MMW Fortschr Med; 2004; 146 Suppl 1():7. PubMed ID: 15493410 [No Abstract] [Full Text] [Related]
17. [Determination of apolipoproteins in the study of clinical atherosclerosis]. Valderová J; Válek J; Vondra K; Fabián J; Grajnetter D; Belán A Vnitr Lek; 1987 Feb; 33(2):117-22. PubMed ID: 3824935 [No Abstract] [Full Text] [Related]
18. [ Lipids--lipoproteins--apolipoproteins--risk markers in atherosclerosis]. Slimane MN; Bouslama A; Maatoug F; Hammami M; Ben Farhat MH Tunis Med; 1992 Feb; 70(2):91-6. PubMed ID: 1496741 [No Abstract] [Full Text] [Related]
19. Invasive versus noninvasive studies of risk factors and atherosclerosis. Sharrett AR Circulation; 1993 Mar; 87(3 Suppl):II48-53. PubMed ID: 8443923 [TBL] [Abstract][Full Text] [Related]
20. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Lee AJ; Fowkes FG; Lowe GD; Connor JM; Rumley A Thromb Haemost; 1999 Apr; 81(4):553-60. PubMed ID: 10235438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]